.gif "IP Gear")
- Joined
- Sep 14, 2016
- Messages
- 218
Just ran across some info while researching,and this article talks about the labido effect of dosing it ,I thought was interesting my self
Cabergoline (CABER)
Cabergoline (aka Dostinex)
(1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea)
Cabergoline (pronounced ca-ber-goe-leen) is a long acting dopamine agonist which acts mainly on the D2 receptors. It is used to treat different types of medical problems that may occur when the body produces an excess of the hormone prolactin. It can also be used to treat menstrual problems in women, fertility problems in both men and women, and it also helps treat pituitary prolactinomas (pituitary gland tumors). Cabergoline is also reported to have some efficacy in patients with Nelson's syndrome and Cushing's disease, but data are available only for limited case reports.
Cabergoline works by signaling the brain to stop the pituitary gland from producing and releasing the prolactin hormone. It is usually used for periods of up to six months after prolactin levels return to normal. You can of course start using it again if high prolactin symptoms reappear later. Prolactin is a single chain protein hormone, similar to growth hormone, that stimulates the secretion of milk by women. Prolactin also effects male libido by preventing erections.
Below is a study done by the University of Naples in Italy, it compares treatment with cabergoline to bromocriptine.
This study evaluated the effects of chronic treatment with cabergoline (CAB), a new, potent and long-lasting ergoline-derived dopamine agonist, on seminal fluid parameters and sexual and gonadal function in hyperprolactinemic males in comparison with the effect of bromocriptine (BRC) treatment. Seventeen males with macroprolactinoma were treated with CAB at a dose of 0.5-1.5 mg/week (n = 7), or BRC at a dose of 5-15 mg/day (n = 10) for 6 months. Baseline prolactin (PRL) was 925.7 +/- 522.6 microg/l in the CAB-treated group and 1059.4 +/- 297.6 microg/l in the BRC-treated group. All the patients suffered from libido impairment, ten from reduced sexual potency, and six had infertility. In five patients provocative bilateral galactorrhea was found. Seminal fluid analysis, functional seminal tests and penis rigidity and tumescence, measured by nocturnal penile tumescence (NPT) using Rigiscan equipment, were assessed before and after 1, 3 and 6 months of CAB or BRC treatment. Hormone profiles were assessed before and after 15, 30, 60, 90 and 180 days of both treatments. Before treatment, all patients had a low sperm count with oligoasthenospermia, reduced motility and rapid progression with an abnormal morphology and decreased viability, and a low number of erections. After 1 month, serum PRL levels were significantly reduced in both groups of patients (20.6 +/- 6.6 microg/l during CAB and 256.3 +/- 115.1 microg/l during BRC treatment) and were normalized after 6 months in all patients (CAB: 7.9 +/- 2.2 microg/l; BRC: 16.7 +/- 1.8 microg/l). After 6 months, a significant increase of number, total motility, rapid progression and normal morphology was recorded in patients treated with both CAB and BRC. An increase in the number of erections during the first 3 months of both treatments was noted by NPT. However, the improvements in seminal fluid parameters and sexual function were more evident and rapid in patients treated with CAB. The number of erections was normalized after 6 months of treatment in all patients submitted to CAB treatment, and in all patients but one treated by BRC. In addition, a significant increase of serum testosterone (from 3.7 +/- 0.3 to 5.3 +/- 0.2 microg/l) and dihydrotestosterone (from 0.4 +/- 0.1 to 1.1 +/- 0.1 nmol/l) was recorded. At the beginning of treatment, mild side-effects were recorded in two patients after CAB and mild-to-moderate side-effects in five patients after BRC administration. The treatment with CAB normalized PRL levels, improving gonadal and sexual function and fertility in males with prolactinoma, earlier than did BRC treatment, providing good tolerability and excellent patient compliance to medical treatment. Cabergoline is normally used were treatment with bromocriptine has failed.
The dose of cabergoline will vary do to the use it is needed for. The following information includes only the average doses of cabergoline in oral dose form. For high prolactin levels or pituitary tumors use 0.25mg/2xwk. This dose can be increased every four weeks if needed because of high sustaining prolactin levels. Usually no more than 1mg/2xwk is needed. The reason for the four week waiting period before adjusting the dose is due to the long half life of the drug. Unlike bromo which should be dosed twice a day, cabergoline is usually dosed once or twice a week.
Men may get another added bonus when using cabergoline, as it has been found to substantially raise the chances of multiple orgasms in males during sex. Some men on the drug reported to have numerous multiple orgasms in rapid succession. In one study done by M. Schedlowski involved 60 male subjects between the ages of 20 to 30. It was found that they normally needed a break of approximately 20 minutes between sessions of sex. After receiving treatment with cabergoline they were able to have several orgasms within a span of a few minutes. Schedlowski said the drug raised the libido to enable the male to orgasm again more quickly. This is do to the fact that it reduces prolactin levels which is produced by men at the point of orgasm.
Some of the most common side effects you may encounter when using this drug are abdominal pain, or vertigo (the feeling that you are weightless or objects are moving around you). Other side effects like constipation, headaches, nausea and weakness may occur, but will most likely stop after your body gets use to the drug. Some of the less common side effects are a change in vision, dizziness, feeling faint when standing up after sitting or lying down, loss of appetite, loss or gain in weight, your hands, feet, or legs may swell up, and rapid heartbeat. Other less common sides include burning, itching or a stinging feeling of the skin, diarrhea, cotton mouth, muscle and joint pain, sore throat, trouble sleeping and a runny nose. Most dopamine drugs are well tolerated by most so the above mentioned side effects are rare. To help prevent some sides, take your dose with food.
Some symptoms of a possible overdose include fainting, hallucinations, lightheadedness, abnormally fast heart rate, and stuffy nose.
An interaction may occur if you use cabergoline with any anti-psychotic medicine or metoclopramide (used to treat stomach problems). Cabergoline should not be used if you suffer from the ailments such as untreated high blood pressure, cabergoline usually decreases blood pressure but at times it may increase it maken your condidtion worse. Also if you suffer from mild to severe liver disease, cabergoline may make you condition worse. In this case a lower dose may be all that is required.
Cabergoline (CABER)
Cabergoline (aka Dostinex)
(1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea)
Cabergoline (pronounced ca-ber-goe-leen) is a long acting dopamine agonist which acts mainly on the D2 receptors. It is used to treat different types of medical problems that may occur when the body produces an excess of the hormone prolactin. It can also be used to treat menstrual problems in women, fertility problems in both men and women, and it also helps treat pituitary prolactinomas (pituitary gland tumors). Cabergoline is also reported to have some efficacy in patients with Nelson's syndrome and Cushing's disease, but data are available only for limited case reports.
Cabergoline works by signaling the brain to stop the pituitary gland from producing and releasing the prolactin hormone. It is usually used for periods of up to six months after prolactin levels return to normal. You can of course start using it again if high prolactin symptoms reappear later. Prolactin is a single chain protein hormone, similar to growth hormone, that stimulates the secretion of milk by women. Prolactin also effects male libido by preventing erections.
Below is a study done by the University of Naples in Italy, it compares treatment with cabergoline to bromocriptine.
This study evaluated the effects of chronic treatment with cabergoline (CAB), a new, potent and long-lasting ergoline-derived dopamine agonist, on seminal fluid parameters and sexual and gonadal function in hyperprolactinemic males in comparison with the effect of bromocriptine (BRC) treatment. Seventeen males with macroprolactinoma were treated with CAB at a dose of 0.5-1.5 mg/week (n = 7), or BRC at a dose of 5-15 mg/day (n = 10) for 6 months. Baseline prolactin (PRL) was 925.7 +/- 522.6 microg/l in the CAB-treated group and 1059.4 +/- 297.6 microg/l in the BRC-treated group. All the patients suffered from libido impairment, ten from reduced sexual potency, and six had infertility. In five patients provocative bilateral galactorrhea was found. Seminal fluid analysis, functional seminal tests and penis rigidity and tumescence, measured by nocturnal penile tumescence (NPT) using Rigiscan equipment, were assessed before and after 1, 3 and 6 months of CAB or BRC treatment. Hormone profiles were assessed before and after 15, 30, 60, 90 and 180 days of both treatments. Before treatment, all patients had a low sperm count with oligoasthenospermia, reduced motility and rapid progression with an abnormal morphology and decreased viability, and a low number of erections. After 1 month, serum PRL levels were significantly reduced in both groups of patients (20.6 +/- 6.6 microg/l during CAB and 256.3 +/- 115.1 microg/l during BRC treatment) and were normalized after 6 months in all patients (CAB: 7.9 +/- 2.2 microg/l; BRC: 16.7 +/- 1.8 microg/l). After 6 months, a significant increase of number, total motility, rapid progression and normal morphology was recorded in patients treated with both CAB and BRC. An increase in the number of erections during the first 3 months of both treatments was noted by NPT. However, the improvements in seminal fluid parameters and sexual function were more evident and rapid in patients treated with CAB. The number of erections was normalized after 6 months of treatment in all patients submitted to CAB treatment, and in all patients but one treated by BRC. In addition, a significant increase of serum testosterone (from 3.7 +/- 0.3 to 5.3 +/- 0.2 microg/l) and dihydrotestosterone (from 0.4 +/- 0.1 to 1.1 +/- 0.1 nmol/l) was recorded. At the beginning of treatment, mild side-effects were recorded in two patients after CAB and mild-to-moderate side-effects in five patients after BRC administration. The treatment with CAB normalized PRL levels, improving gonadal and sexual function and fertility in males with prolactinoma, earlier than did BRC treatment, providing good tolerability and excellent patient compliance to medical treatment. Cabergoline is normally used were treatment with bromocriptine has failed.
The dose of cabergoline will vary do to the use it is needed for. The following information includes only the average doses of cabergoline in oral dose form. For high prolactin levels or pituitary tumors use 0.25mg/2xwk. This dose can be increased every four weeks if needed because of high sustaining prolactin levels. Usually no more than 1mg/2xwk is needed. The reason for the four week waiting period before adjusting the dose is due to the long half life of the drug. Unlike bromo which should be dosed twice a day, cabergoline is usually dosed once or twice a week.
Men may get another added bonus when using cabergoline, as it has been found to substantially raise the chances of multiple orgasms in males during sex. Some men on the drug reported to have numerous multiple orgasms in rapid succession. In one study done by M. Schedlowski involved 60 male subjects between the ages of 20 to 30. It was found that they normally needed a break of approximately 20 minutes between sessions of sex. After receiving treatment with cabergoline they were able to have several orgasms within a span of a few minutes. Schedlowski said the drug raised the libido to enable the male to orgasm again more quickly. This is do to the fact that it reduces prolactin levels which is produced by men at the point of orgasm.
Some of the most common side effects you may encounter when using this drug are abdominal pain, or vertigo (the feeling that you are weightless or objects are moving around you). Other side effects like constipation, headaches, nausea and weakness may occur, but will most likely stop after your body gets use to the drug. Some of the less common side effects are a change in vision, dizziness, feeling faint when standing up after sitting or lying down, loss of appetite, loss or gain in weight, your hands, feet, or legs may swell up, and rapid heartbeat. Other less common sides include burning, itching or a stinging feeling of the skin, diarrhea, cotton mouth, muscle and joint pain, sore throat, trouble sleeping and a runny nose. Most dopamine drugs are well tolerated by most so the above mentioned side effects are rare. To help prevent some sides, take your dose with food.
Some symptoms of a possible overdose include fainting, hallucinations, lightheadedness, abnormally fast heart rate, and stuffy nose.
An interaction may occur if you use cabergoline with any anti-psychotic medicine or metoclopramide (used to treat stomach problems). Cabergoline should not be used if you suffer from the ailments such as untreated high blood pressure, cabergoline usually decreases blood pressure but at times it may increase it maken your condidtion worse. Also if you suffer from mild to severe liver disease, cabergoline may make you condition worse. In this case a lower dose may be all that is required.
